What It Is
MOTS-c is an unusually short, 16-amino-acid peptide notable for where it comes from: it is encoded by mitochondrial DNA itself, within a region called MT-RNR1 that was previously thought to only produce ribosomal RNA. It belongs to a small, newly described class called mitochondrial-derived peptides, alongside a related molecule called humanin.[1]
It was first described in a 2015 study as a regulator of metabolic homeostasis in mice, and research interest since has focused on metabolism, exercise physiology, and cellular energy signaling rather than any established medical use.
How It Works
MOTS-c is proposed to act as a messenger between mitochondria and the rest of the cell, including the nucleus. In animal and cell studies it activates AMPK, a central cellular energy-sensing enzyme, and interacts with folate and purine metabolism pathways tied to glucose handling.[1] Under metabolic stress, MOTS-c has been shown to move into the cell nucleus and influence gene expression, a process researchers call mitochondrial-to-nuclear retrograde signaling.
This is a genuinely novel signaling mechanism, but it is also complex and only partly mapped — a plausible mechanism in mice and cells is not the same as a proven effect in people.
What the Research Shows
Nearly all detailed findings come from mouse and cell studies. In diet-induced-obesity mouse models, MOTS-c administration improved insulin-sensitivity measures and reduced weight gain.[1] A later study described MOTS-c as an exercise-induced regulator linked to age-related physical decline and muscle function in mice, with supporting human observations correlating blood MOTS-c levels with age and exercise.[3]
Human data are essentially limited to observational plasma-level measurements, not interventional trials of injected MOTS-c. No registered clinical trials currently establish the efficacy or safety of exogenous MOTS-c in people.
The Mitochondrial and Exercise-Mimetic Angle
MOTS-c's research niche sits squarely at the intersection of mitochondrial biology and exercise physiology. It is often discussed as an "exercise mimetic" candidate because it appears to link physical activity to metabolic gene expression and muscle maintenance in aging mice.
This research angle has fed into online longevity and performance marketing, but claims that MOTS-c administration improves human athletic performance, slows aging, or treats metabolic disease go well beyond what current mouse-and-cell evidence supports.
Safety & Side Effects
Because MOTS-c has never been tested in controlled human clinical trials, there is no established human side-effect profile, no defined contraindications, and no data on long-term safety, immune effects, or interactions with diabetes medications. Preclinical toxicity data are limited to the animal studies described above.
Products sold online as research-grade MOTS-c carry the same sourcing, purity, and sterility uncertainty common to unregulated peptides, on top of the underlying lack of human safety data.
Regulatory Status
MOTS-c has no FDA approval, no approved indication, and does not appear in FDA drug-approval databases.[4] It is sold and studied strictly as a research chemical, with no regulator-reviewed label defining safe human use in any jurisdiction.